The historical rank and industry rank for Regenerx Biopharmaceuticals's Operating Margin % or its related term are showing as below:
RGRX's Operating Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -86.77 * Ranked among companies with meaningful Operating Margin % only.
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Regenerx Biopharmaceuticals Operating Margin % Related Terms
Regenerx Biopharmaceuticals Operating Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RGRX vs MYMX, RGMP, NBRVF: Operating Margin % Comparison
For the Biotechnology subindustry, Regenerx Biopharmaceuticals's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regenerx Biopharmaceuticals Operating Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Regenerx Biopharmaceuticals's Operating Margin % distribution charts can be found below:
* The bar in red indicates where Regenerx Biopharmaceuticals's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Regenerx Biopharmaceuticals's Operating Margin % for the fiscal year that ended in Dec. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Operating Margin % of -1,605.26% mean?
Regenerx Biopharmaceuticals (RGRX) has a Operating Margin % of -1,605.26% as of Mar. 2023. Operating margin is the ratio of total operating income to net sales. View historical data on Regenerx Biopharmaceuticals and its competitors.
Is Regenerx Biopharmaceuticals' Operating Margin % too high?
Regenerx Biopharmaceuticals' current Operating Margin % is -1,605.26%.
How does Regenerx Biopharmaceuticals' Operating Margin % compare to MYMX and RGMP?
Regenerx Biopharmaceuticals' Operating Margin % of -1,605.26% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Regenerx Biopharmaceuticals and its competitors. Regenerx Biopharmaceuticals's current Operating Margin % is -1,605.26%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regenerx Biopharmaceuticals stock overvalued right now?
Regenerx Biopharmaceuticals (RGRX) has a current Operating Margin % of -1,605.26%. The current Operating Margin % is -1,605.26%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Regenerx Biopharmaceuticals (RGRX), the current Operating Margin % is -1,605.26% as of Mar. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Regenerx Biopharmaceuticals Inc is focused on the discovery and development of novel molecules to accelerate tissue and organ repair. Its operations are confined to one business segment: the development and marketing of product candidates based on Thymosin Beta 4 (Tß4), an amino acid peptide. The company has formulated Tß4 into three distinct product candidates in clinical development: RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease or other pathology; RGN-137, a topical gel for dermal wounds and reduction of scar tissue; and RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications that may be treated by systemic administration.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RGRX has been successfully added to your 